<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS/HYPOTHESIS: <z:chebi fb="27" ids="27300">Vitamin D</z:chebi> is necessary for <z:mpath ids='MPATH_458'>normal</z:mpath> insulin action and suppresses renin production </plain></SENT>
<SENT sid="1" pm="."><plain>Increased renin-angiotensin system (<z:mp ids='MP_0011356'>RAS</z:mp>) activity causes islet damage, including <z:mp ids='MP_0003059'>reduced insulin secretion</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>We therefore sought to determine whether <z:e sem="disease" ids="C1510471" disease_type="Disease or Syndrome" abbrv="">hypovitaminosis</z:e> D-induced upregulation of islet <z:mp ids='MP_0011356'>RAS</z:mp> in vivo impairs islet cell function and increases <z:hpo ids='HP_0000855'>insulin resistance</z:hpo>, and whether pharmacological suppression of the <z:mp ids='MP_0011356'>RAS</z:mp> during continuing <z:hpo ids='HP_0100512'>vitamin D deficiency</z:hpo> might correct this </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: C57BL/6 mice were rendered <z:chebi fb="27" ids="27300">vitamin D</z:chebi>-deficient by diet, and <z:chebi fb="105" ids="17234">glucose</z:chebi> and insulin tolerance was assessed </plain></SENT>
<SENT sid="4" pm="."><plain>The expression and translation of islet functional, and islet <z:mp ids='MP_0011356'>RAS</z:mp>, genes were measured and the effects of pharmacological renin suppression examined </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Mice with diet-induced <z:e sem="disease" ids="C1510471" disease_type="Disease or Syndrome" abbrv="">hypovitaminosis</z:e> D developed <z:hpo ids='HP_0000833'>impaired glucose tolerance</z:hpo>, increased <z:mp ids='MP_0011356'>RAS</z:mp> component expression and impaired islet function gene transcription </plain></SENT>
<SENT sid="6" pm="."><plain>Treatment with pharmacological renin inhibition (<z:chebi fb="0" ids="601027">aliskiren</z:chebi>), without <z:chebi fb="27" ids="27300">vitamin D</z:chebi> status correction, reduced islet <z:mp ids='MP_0011356'>RAS</z:mp> over-reactivity, islet dysfunction and <z:hpo ids='HP_0000855'>insulin resistance</z:hpo>, and <z:mp ids='MP_0005292'>improved glucose tolerance</z:mp> </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS/INTERPRETATION: Upregulation of islet <z:mp ids='MP_0011356'>RAS</z:mp> genes can contribute to <z:e sem="disease" ids="C1510471" disease_type="Disease or Syndrome" abbrv="">hypovitaminosis</z:e> D-induced impairment of islet function and increase <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> independently of <z:chebi fb="27" ids="27300">vitamin D</z:chebi> status </plain></SENT>
<SENT sid="8" pm="."><plain>Thus, our findings support the use of <z:mp ids='MP_0011356'>RAS</z:mp> inhibitors in impaired <z:chebi fb="105" ids="17234">glucose</z:chebi> homeostasis or early <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="9" pm="."><plain>They also suggest that combining <z:mp ids='MP_0011356'>RAS</z:mp> inhibition with correction of <z:e sem="disease" ids="C1510471" disease_type="Disease or Syndrome" abbrv="">hypovitaminosis</z:e> D might be useful in treating impaired glycaemic control and also in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> prevention </plain></SENT>
<SENT sid="10" pm="."><plain>However, the use of <z:chebi fb="0" ids="601027">aliskiren</z:chebi> in established <z:mp ids='MP_0002055'>diabetes</z:mp> is contraindicated due to the increased risk of side effects such as hyperkalaemia, so other more suitable <z:mp ids='MP_0011356'>RAS</z:mp> blockers need to be identified </plain></SENT>
</text></document>